A mutant HSV(mtHSV) deleted icp34.5,an apoptosis-inhibiting gene w a s constructed. It is supposed that the mtHSV can replicate in p53-deficient cel l s selectively and lead to oncolysis targetedly. Mice tumor model harboring sarco ma cell line s-180 was developed and the mtHSV was injected into the tumors. We found that the mean volume and weight of tumors of early therapeutic group(ETG) were reduced 49.29% and 38.31% of that of control tumors .In t he mid|term group(MTG),the redutcion rate were 26.9% and 24.52% respectively.
展开▼
